Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
EnteraBio's Parathyroid Hormone · 1 trial · 1 indication
safety will be measured by monitoring and recording adverse events related to hyper- and hypocalcemia
To study the pharmacokinetic profile of PTH absorption
| Arm | Type | Description |
|---|---|---|
| Oral Parathyroid Hormone (1-34) | EXPERIMENTAL | Oral administration of EnteraBio's Oral Parathyroid Hormone (1-34) |
| Name | Type | Description |
|---|---|---|
| EnteraBio's Oral Parathyroid Hormone (1-34) | DRUG | Oral administration |
Inclusion Criteria: * Confirmed diagnosis of primary hypoparathyroidism for more than 1 year. * Currently taking \>1.0 grams of Calcium/day with a correlate alpha D3 dose. * 25(OH)D levels ≥ 20 ng/ml. * Signed informed consent. * BMI 18 - 30 kg/m2, inclusive. * Full blood count should be within the...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AstraZeneca PLC | AZN | 1 | PHASE3 | eneboparatide |
| Ascendis Pharma A/S | ASND | 3 | PHASE3 | Palopegteriparatide Experimental Arm, Palopegteriparatide Control Arm |
| MBX Biosciences, Inc. | MBX | 1 | PHASE2 | 400 µg of MBX 2109 once-weekly by, 200-1600 µg of MBX 2109 once-weekly by |
EnteraBio's Parathyroid Hormone is an investigational oral small molecule being developed for the treatment of hypoparathyroidism, a condition characterized by insufficient parathyroid hormone. It is currently in Phase 2 clinical development and is not yet approved by regulatory authorities.
EnteraBio's Parathyroid Hormone is being developed by Entera Bio Ltd., a biopharmaceutical company traded on the NASDAQ under the ticker symbol ENTX. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational therapy for hypoparathyroidism.
EnteraBio's Parathyroid Hormone is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory agencies and is still undergoing clinical trials to assess its safety and effectiveness in patients with hypoparathyroidism.
EnteraBio's Parathyroid Hormone has one completed Phase 2 clinical trial, identified as NCT02152228. This was a pilot study conducted in Israel to assess the safety and efficacy of oral PTH (1-34) in the treatment of hypoparathyroidism, enrolling 20 adult participants.
Yes, EnteraBio's Parathyroid Hormone is also known as oral PTH (1-34), as referenced in the clinical trial title. This investigational therapy is being studied for its potential to treat hypoparathyroidism through oral administration of parathyroid hormone.